#marketingapplications

AZ is three for three with COPD hope tozorakimab AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

#AstraZeneca's IL-33-targeting antibody #tozorakimab has hit the target in the third of three phase 3 trials in #chronicobstructivepulmonarydisease (COPD), making a clean sweep of results and setting up #marketingapplications.

pharmaphorum.com/news/az-thre...